Wedbush Reiterates Outperform Rating for Aimmune Therapeutics (AIMT)

Wedbush reiterated their outperform rating on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a report issued on Monday morning.

A number of other equities analysts have also issued reports on AIMT. Zacks Investment Research raised shares of Aimmune Therapeutics from a sell rating to a hold rating in a research report on Monday, October 16th. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a research report on Saturday, October 21st. Credit Suisse Group boosted their target price on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an outperform rating in a research report on Monday, October 23rd. Roth Capital started coverage on shares of Aimmune Therapeutics in a research report on Monday, November 20th. They set a buy rating and a $60.00 target price on the stock. Finally, ValuEngine lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $57.25.

Aimmune Therapeutics (NASDAQ:AIMT) opened at $38.24 on Monday. Aimmune Therapeutics has a 52-week low of $15.97 and a 52-week high of $40.65. The company has a market cap of $1,950.00 and a P/E ratio of -16.34.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. equities analysts anticipate that Aimmune Therapeutics will post -2.51 earnings per share for the current fiscal year.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction on Monday, February 5th. The shares were sold at an average price of $35.87, for a total transaction of $59,113.76. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mary M. Rozenman sold 6,592 shares of Aimmune Therapeutics stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $35.36, for a total transaction of $233,093.12. The disclosure for this sale can be found here. Insiders have sold 134,294 shares of company stock worth $5,097,144 in the last ninety days. 24.56% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James & Associates boosted its stake in Aimmune Therapeutics by 7.2% during the fourth quarter. Raymond James & Associates now owns 24,737 shares of the biotechnology company’s stock worth $936,000 after buying an additional 1,669 shares in the last quarter. American International Group Inc. boosted its stake in Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after buying an additional 1,764 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Aimmune Therapeutics by 3.1% during the fourth quarter. Wells Fargo & Company MN now owns 63,158 shares of the biotechnology company’s stock worth $2,388,000 after buying an additional 1,892 shares in the last quarter. Daiwa SB Investments Ltd. boosted its stake in Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after buying an additional 2,245 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in Aimmune Therapeutics by 54.7% during the third quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after buying an additional 2,979 shares in the last quarter. Hedge funds and other institutional investors own 73.14% of the company’s stock.

WARNING: “Wedbush Reiterates Outperform Rating for Aimmune Therapeutics (AIMT)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/16/wedbush-reiterates-outperform-rating-for-aimmune-therapeutics-aimt.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply